News
Intertek partners with CrystecPharma to advance formulation science and accelerate development timelines for dry powder inhaler products
Cambridge, UK: Intertek, a leading Total Quality Assurance provider to industries worldwide, is pleased to announce that it has entered a partnership with CrystecPharma, focusing on advancing formulation science and accelerating development timelines for inhaled medicines, particularly dry powder inhaler (DPI) products.
Crystec is attending DDL 2024 in Edinburgh, UK
Crystec is delighted to be attending DDL 2024 (Drug Delivery to the Lungs) on its 35-year anniversary at Edinburgh International Conference Centre, from December 11th to December 13th.
Crystec is attending the 3rd Annual Inhaled & Nasal Biologics / DNA Forum in Cambridge, UK
Crystec is thrilled to be attending the 3rd Annual Inhaled & Nasal Biologics / DNA Forum in Cambridge, UK, on September 26th and 27th!
Rapid Solid-State Screening
For pharmaceutical and biotechnology companies, it is important to identify as many polymorphic forms of a small molecule therapeutic as possible, to mitigate threats from competitors and to create opportunities to optimise product performance.
Particle Engineering to Optimise the Performance of Inhaled Therapeutics
The Crystec mSAS® (modified supercritical anti-solvent) process offers distinct advantages in the development of high-performing inhaled products.
Crystec at #CPhI2023
Meet with the Crystec team at CPhI2023 in Barcelona to explore how we can transform the performance of medicines together.
Next-Generation Biomanufacturing
mSAS® supercritical fluid technology marks a significant step forward in the stabilisation and processing of biomolecules.
Meet Crystec at BIO2023
Exciting times ahead at #BIO2023 in Boston! Join us as we bring together the brightest minds in biotechnology to discuss the latest breakthroughs and innovations. Don’t miss this opportunity to network, learn, and collaborate.
